Ultragenyx Pharmaceutical (RARE) Research & Development (2013 - 2026)
Ultragenyx Pharmaceutical's Research & Development came in at $167 million for Q2 2026, up 1.2% from $165 million a year earlier but down 10.7% from the prior quarter.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Research & Development (2013 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Ultragenyx Pharmaceutical reported Research & Development of $773.49 million, up 12.3% year-over-year; for FY2025, it was $750 million, up 7.4% from FY2024.
- Research & Development carries a five-year compound annual growth rate of 12.7% (FY2020 to FY2025).
- Going back by year, Research & Development was $698 million in FY2024 (+7.7%), $648 million in FY2023 (-8.2%), $705.79 million in FY2022 (+42.0%) and $497.15 million in FY2021 (+20.6%).
- The five-year range for quarterly Research & Development is $113.42 million (Q3 2021) to $237.3 million (Q3 2022).
- Year-over-year, Research & Development has increased for five consecutive quarters, with growth averaging 8.7% over the last eight quarters.
- The fastest year-over-year change in Research & Development over five years came in Q3 2022 (growth of 109.2%), and the weakest in Q3 2023 (a decline of 33.7%).
- Business Quant data shows RARE's Research & Development at $187 million (Q1 2026), $203.28 million (Q4 2025) and $216.21 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,230.11 Bn | 1,198.70 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 644.39 Bn | 564.25 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 503.52 Bn | 476.68 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 363.29 Bn | 317.72 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.23 Bn | 262.62 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 267.53 Bn | 241.29 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 241.80 Bn | 197.20 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 195.07 Bn | 169.19 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 173.33 Bn | 120.28 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Ultragenyx Pharmaceutical | 1.57 Bn | -230.58 Mn | 180.00 Mn | 167.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 167.00 Mn |
| Mar 31, 2026 | 187.00 Mn |
| Dec 31, 2025 | 203.28 Mn |
| Sep 30, 2025 | 216.21 Mn |
| Jun 30, 2025 | 165.00 Mn |
| Mar 31, 2025 | 166.00 Mn |
| Dec 31, 2024 | 187.90 Mn |
| Sep 30, 2024 | 170.11 Mn |
| Jun 30, 2024 | 161.50 Mn |
| Mar 31, 2024 | 178.49 Mn |
| Dec 31, 2023 | 160.11 Mn |
| Sep 30, 2023 | 157.25 Mn |
| Jun 30, 2023 | 164.95 Mn |
| Mar 31, 2023 | 165.70 Mn |
| Dec 31, 2022 | 170.81 Mn |
| Sep 30, 2022 | 237.30 Mn |
| Jun 30, 2022 | 154.53 Mn |
| Mar 31, 2022 | 143.16 Mn |
| Dec 31, 2021 | 123.01 Mn |
| Sep 30, 2021 | 113.42 Mn |
API Access
Ultragenyx Pharmaceutical Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=RARE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "RARE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=RARE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();